mRNA & Non-viral Delivery - Live Online Training

The primary objective of this two-day course, is to provide participants with a comprehensive understanding of the latest breakthroughs in non-viral transduction methods for cell therapy. Designed for professionals in the pharmaceutical and biotechnology sectors, the course aims to foster a deeper appreciation of RNA-based medicinal products, non-viral delivery systems, and their transformative potential in advancing cell therapies.

By the end of the course, participants will have a robust understanding of both the scientific principles and practical applications of RNA and non-viral technologies, enabling them to contribute to the development of innovative and patient-centric therapies.

Background

Innovations in cell therapies have revolutionized the pharmaceutical and biotech industries, unlocking unprecedented possibilities for treating previously incurable diseases. Traditional viral transduction methods, while effective, face significant challenges, including scalability, high production costs, and potential immunogenicity. To address these limitations, virus-free transduction technologies have emerged as promising alternatives, enabling safer, more efficient, and scalable cell engineering solutions.

At the forefront of these innovations is the use of RNA, a versatile biomolecule that has transformed therapeutic approaches in various domains. The success of mRNA-based vaccines, exemplified by the BioNTech COVID-19 vaccine, has demonstrated the molecule's potential to drive rapid and targeted therapeutic development. Beyond vaccines, RNA is increasingly utilized in personalized medicine, particularly in cancer therapies, where patient-specific RNA-based treatments are being explored.

Non-viral delivery platforms, including lipid nanoparticles (LNPs), electroporation, and cell squeeze technologies, have emerged as game-changing tools in cell therapy. These systems offer distinct advantages, such as reduced toxicity, enhanced delivery efficiency, and streamlined manufacturing processes. By eliminating the risks associated with viral vectors, these technologies pave the way for more accessible and patient-friendly therapies.

Despite these advancements, the regulatory and manufacturing landscapes for virus-free transduction methods remain complex. Developing robust quality control measures and adhering to stringent GMP requirements are critical for ensuring the safety and efficacy of these therapies. Furthermore, understanding the comparative strengths and weaknesses of viral and non-viral systems is essential for informed decision-making in therapeutic development.

This course is designed to address the knowledge gaps in this rapidly evolving field, offering professionals a unique opportunity to engage with experts and gain practical insights into the future of RNA and non-viral cell therapy platforms.

With a focus on real-world applications, cutting-edge research, and regulatory considerations, the program equips participants with the tools to drive innovation in their respective fields.